| Authors: |
Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO 80218, USA., Costello CL; Department of Medicine, Division of Blood & Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Birhiray RE; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN 46260, USA., Kambhampati S; Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA., Richter J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Stokes M; Evidera, Data Analytics, St-Laurent, Quebec, H4T 1V6, Canada., Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Bogard K; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Noga SJ; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Girnius S; TriHealth Cancer Institute, Cincinnati, OH 45247, USA. |
